Skip to main content

Consumption of Bifidobacterium animalis subsp. lactis BB-12 in yogurt reduced expression of TLR-2 on peripheral blood-derived monocytes and pro-inflammatory cytokine secretion in young adults

  • 2015-11-30
  • European Journal of Nutrition 56(2)
    • Huicui Meng
    • Zhaoyong Ba
    • Yujin Lee
    • Jiayu Peng
    • Junli Lin
    • J. Fleming
    • E. Furumoto
    • R. Roberts
    • P. Kris-Etherton
    • C. Rogers

Abstract

Purpose: Probiotic bacteria modulate immune parameters and inflammatory outcomes. Emerging evidence demonstrates that the matrix used to deliver probiotics may influence the efficacy of probiotic interventions in vivo. The aims of the current study were to evaluate (1) the effect of one species, Bifidobacterium animalis subsp. lactis BB-12 at a dose of log10 ± 0.5 CFUs/day on immune responses in a randomized, partially blinded, 4-period crossover, free-living study, and (2) whether the immune response to BB-12 differed depending on the delivery matrix.

Methods: Healthy adults (n = 30) aged 18-40 years were recruited and received four treatments in a random order: (A) yogurt smoothie alone; smoothie with BB-12 added (B) before or (C) after yogurt fermentation, or (D) BB-12 given in capsule form. At baseline and after each 4-week treatment, peripheral blood mononuclear cells (PBMCs) were isolated, and functional and phenotypic marker expression was assessed.

Results: BB-12 interacted with peripheral myeloid cells via Toll-like receptor 2 (TLR-2). The percentage of CD14+HLA-DR+ cells in peripheral blood was increased in male participants by all yogurt-containing treatments compared to baseline (p = 0.0356). Participants who consumed yogurt smoothie with BB-12 added post-fermentation had significantly lower expression of TLR-2 on CD14+HLA-DR+ cells (p = 0.0186) and reduction in TNF-α secretion from BB-12- (p = 0.0490) or LPS-stimulated (p = 0.0387) PBMCs compared to baseline.

Conclusions: These findings not only demonstrate a potential anti-inflammatory effect of BB-12 in healthy adults, but also indicate that the delivery matrix influences the immunomodulatory properties of BB-12.

Keywords: BB-12; Delivery matrix; Inflammation; Probiotics; TNF-α.

Research Insights

SupplementHealth OutcomeEffect TypeEffect Size
Bifidobacterium animalis subsp. lactisReduced TLR-2 Expression on CD14+HLA-DR+ CellsBeneficial
Moderate
Bifidobacterium animalis subsp. lactisReduced TNF-α SecretionBeneficial
Moderate
Bifidobacterium animalis subsp. lactis B420Reduced Pro-inflammatory Cytokines TNF-α LevelsBeneficial
Moderate
Bifidobacterium animalis subsp. lactis B420Reduced TLR-2 Expression on MonocytesBeneficial
Moderate
Bifidobacterium animalis subsp. lactis BLC1Increased CD14+HLA-DR+ Cells in Peripheral BloodBeneficial
Small
Bifidobacterium animalis subsp. lactis BLC1Reduced TLR-2 Expression on CD14+HLA-DR+ CellsBeneficial
Moderate
Bifidobacterium animalis subsp. lactis BLC1Reduced TNF-α SecretionBeneficial
Moderate
Bifidobacterium animalis subsp. lactis BS-01Increased CD14+HLA-DR+ Cells in Peripheral BloodBeneficial
Small
Bifidobacterium animalis subsp. lactis BS-01Reduced Proinflammatory Cytokine SecretionBeneficial
Moderate
Bifidobacterium animalis subsp. lactis BS-01Reduced TLR-2 Expression on CD14+HLA-DR+ CellsBeneficial
Moderate
Bifidobacterium animalis subsp. lactis LAFTI B94Increased CD14+HLA-DR+ Cells in Peripheral BloodBeneficial
Small
Bifidobacterium animalis subsp. lactis LAFTI B94Reduced TLR-2 Expression on CD14+HLA-DR+ CellsBeneficial
Moderate
Bifidobacterium animalis subsp. lactis LAFTI B94Reduced TNF-α SecretionBeneficial
Moderate
Bifidobacterium animalis subsp. lactis VK2Increased CD14+HLA-DR+ Cell Percentage in MalesNeutral
Small
Bifidobacterium animalis subsp. lactis VK2Reduced TLR-2 Expression on MonocytesBeneficial
Moderate
Bifidobacterium animalis subsp. lactis VK2Reduced TNF-α SecretionBeneficial
Moderate
Bifidobacterium bifidum BB01Increased CD14+HLA-DR+ Cells in Peripheral BloodBeneficial
Small
Bifidobacterium bifidum BB01Reduced Proinflammatory Cytokine SecretionBeneficial
Moderate
Bifidobacterium bifidum BB01Reduced TLR-2 Expression on MonocytesBeneficial
Moderate
Bifidobacterium bifidum/lactis Bb-02Reduced TLR-2 Expression on MonocytesBeneficial
Moderate
Bifidobacterium bifidum/lactis Bb-02Reduced TNF-α SecretionBeneficial
Moderate
Bifidobacterium lactis Bb-02Reduced Pro-inflammatory Cytokine SecretionBeneficial
Moderate
Bifidobacterium lactis Bb-02Reduced TLR-2 Expression on MonocytesBeneficial
Moderate
Bifidobacterium lactis BB-12Reduced Pro-inflammatory Cytokine SecretionBeneficial
Moderate
Bifidobacterium lactis BB-12Reduced TLR-2 Expression on MonocytesBeneficial
Moderate
Bifidobacterium lactis BL818Reduced Proinflammatory Cytokine SecretionBeneficial
Moderate
Bifidobacterium lactis BLA80Reduced TLR-2 Expression on MonocytesBeneficial
Moderate
Bifidobacterium lactis BLA80Reduced TNF-α SecretionBeneficial
Moderate
Bifidobacterium lactis BLC-1Reduced Inflammatory Marker Protein LevelsBeneficial
Moderate
Bifidobacterium lactis BLC-1Reduced Pro-inflammatory Cytokine SecretionBeneficial
Moderate
Bifidobacterium lactis HDS Bb-02Reduced Pro-inflammatory Cytokine SecretionBeneficial
Moderate
Bifidobacterium lactis HDS Bb-02Reduced TLR-2 Expression on MonocytesBeneficial
Moderate
Bifidobacterium lactis ISS BifReduced Inflammatory Marker Protein LevelsBeneficial
Moderate
Bifidobacterium lactis ISS BifReduced Pro-inflammatory Cytokine SecretionBeneficial
Moderate
Bifidobacterium lactis UABla-12Reduced Pro-inflammatory Cytokine SecretionBeneficial
Moderate
Bifidobacterium lactis UABla-12Reduced TLR-2 Expression on MonocytesBeneficial
Moderate

Pillser helps you make informed health decisions by providing comprehensive, unbiased information about supplements. This includes detailed research on supplement ingredients, their benefits, potential risks, and their overall efficacy. You can contribute by sharing your feedback and suggestions.

Send us an email at support@pillser.com.